GeoVax’s Phase 2a HIV/AIDS Vaccine Trials to Begin
GeoVax Labs, Inc. (Atlanta, GA) will launch its Phase 2a human vaccine trials in 12 sites across North and South America.
GeoVax Labs, Inc. (Atlanta, GA) will launch its Phase 2a human vaccine trials in 12 sites across North and South America. These trials will be conducted in collaboration with the National Institutes of Health (NIH) and the HIV Vaccine Trials Network (HVTN).
Trial site arrangements and other details of the study were confirmed in a recent meeting held in Seattle, WA, between the HVTN and GeoVax’s scientific personnel. The Phase 2a clinical trial will involve 150 vaccinees and 75 placebo participants. The vaccine regimen employs a two-component “prime–boost strategy.” Trial participants will first be administered a GeoVax HIV-1 DNA vaccine which “primes” the immune system, followed by the second vaccine, GeoVax’s HIV-1 MVA (modified Vaccinia virus) boost. Both vaccines express the three major proteins of the AIDS virus. These proteins mimic more than 50% of the components of the AIDS virus (HIV-1) but cannot cause AIDS. GeoVax AIDS vaccines are designed to prevent the HIV-1 virus infection that causes acquired immunodeficiency disease (AIDS).
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
